F-25 Additional drug resistance patterns among multidrug-resistant tuberculosis patients in Korea: Implications for regimen design = F-25 Additional drug resistance patterns among multidrug-resistant tuberculosis patients in Korea: Implications for regimen design

다국어 초록 (Multilingual Abstract)

Nationale: Detailed information on additional drug resistance patterns of multidrug-resistant tuberculosis (MDR-TB) is essen-tial to build an effective treatment regimen; however, such data are scarce in Korea. Methods: We retrospectively analyzed the results of phenotypic drug susceptibility testing (DST) of culture confirmed-TB patients from January 2010 to December 2014 in seven university hospitals in Korea. Results: MDR-TB was identified among 6.8% (n=378) of 5599 isolates. A total of 57.1% (n=216) of the MDR-TB patients had never been treated for TB. Strains from MDR-TB patients showed additional resistance to pyrazinamide (35.7%), any second-line injectable drug (19.3%), and any fluoroquinolone (26.2%). Extensively drug resistant TB comprised 12.4% (n=47) of the MDR-TB patients. Of 378 MDR-TB patients, 50.3% (n=190) were eligible for the shorter MDR-TB regimen, and 50.0% (n=189) were fully susceptible to the five drugs comprising the standard conventional regimen (pyrazinamide, kanamycin, ofloxoacin, prothionamide, and cycloserine). Conculsion: The proportion of new patients and the levels of additional drug resistance were high in MDR-TB patients. Considering the high levels of drug resistance, the shorter MDR-TB treatment regimen may not be feasible; instead, an individually tailored regimen based on the results of molecular and phenotypic DST may be more appropriate in MDR-TB patients in Korea.